Rekombinanter KRT17 Antikörper

Produktnummer ABIN7881373

Der Kaninchen Monoklonal anti-KRT17 Antikörper wird verwendet zum Nachweis von KRT17 in Proben von Human. Er wurde validiert für IHC (p).

Kurzübersicht für Rekombinanter KRT17 Antikörper (ABIN7881373)

Target: KRT17 (Keratin 17 (KRT17))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser KRT17 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Klon: KRT17-8346R

Produktdetails anti-KRT17 Antikörper

Verwendungszweck: Recombinant Keratin 17 Antibody / Cytokeratin 17

Aufreinigung: Protein A/G affinity

Immunogen: A recombinant fragment of human KRT17 protein was used as the immunogen for the recombinant Keratin 17 antibody.

Isotyp: IgG, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the recombinant Keratin 17 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot the recombinant Keratin 17 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Details zu KRT17

Target: KRT17 (Keratin 17 (KRT17))

Andere Bezeichnung: Keratin 17

Hintergrund: Cytokeratin 17 is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. It is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course.

UniProt: Q04695